Mechanosensitive high-throughput screening technology for cytotoxicity and drug studies
CompanyinnoVitro GmbH, Juelich, Germany(1)
Nanion Technologies GmbH, Munich, Germany(2)
Nanion Technologies GmbH, Munich, Germany(2)
The companies innoVitro and Nanion Technologies have jointly developed a high-throughput screening platform (FLEXcyte 96) to assess heart-damaging substances. The technology is based on specially designed 96 cell culture plates (FLEXcyte 96-well plates), whose wafer-thin, hyperelastic silicone membranes mimic the mechanical environment of the heart. The mechanosensitive environment has a positive effect on the maturation of human iPSC-derived heart cells. The maturation process can also be promoted by an optical stimulation method (CardioExcyte 96 SOLE), which can also be used to modulate the heartbeat behavior if required. The cultivation, monitoring and analysis of the contractility and electrophysiology of the cardiac microtissue is carried out with the CardioExcyte 96 (also developed by innnoVitro and Nanion), a software-based, highly sensitive screening technology with an integrated incubation system. CardioExcyte 96 technology enables non-invasive, label-free testing of acute and chronic cardiotoxicity. Cellular damage is recorded using basic impedance parameters. Electric field potentials (EFP) are recorded to assess disturbances in the heart's electrical excitation system. The method was validated by various cytotoxicity studies with human cardiomyocytes and other human cell lines (hepatocyte-like cells, cancer cells). The FLEXcyte 96 technology enables safe and rapid identification of (cardio)toxic agents and can help to accelerate drug development and prevent drug-induced damage.
FLEXcyte 96 and CardioExcyte 96 technologies
info@innoVitro.de(1), info@nanion.de(2)
Added on: 08-01-2023
[1] https://innovitro.de/products/[2] https://www.nanion.de/products/cardioexcyte-96/
